WRF
AEGR

Waddell & Reed Financial’s Aegerion Pharmaceuticals AEGR Stock Holding History

Waddell & Reed Financial’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-130,320
Closed -$6.01M – 581
2014
Q1 		$6.01M Buy
130,320
+44,630
+52% +$2.62M 0.01% 496
2013
Q4 		$6.08M Buy
+85,690
New +$6.55M 0.01% 487

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Waddell & Reed Financial's AEGR Position: Q2 2014 in Review

Waddell & Reed Financial sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 130,320 shares — an estimated $6.01M sold.

Waddell & Reed Financial first reported a position in AEGR in Q4 2013 and held it in 2 quarters. The position peaked at $6.08M in Q4 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Waddell & Reed Financial reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Waddell & Reed Financial sold 130,320 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $6.01M.
  • Waddell & Reed Financial first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Waddell & Reed Financial's Aegerion Pharmaceuticals position peaked at $6.08M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Waddell & Reed Financial's 13F filing for Q2 2014, filed 14 Aug 2014.